m+Medelevator.RU
← Поиск публикаций
Advanced healthcare materials · 2025

Bioengineered Pancreatic Cancer Immunosuppressive Microenvironment Models for Screening Immunotherapies.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Monteiro Maria V, Henriques-Pereira Margarida, Neves Bruno M, Gaspar Vítor M, Mano João F

Аннотация

Pancreatic cancer is notably resistant to treatment, primarily due to its dense desmoplastic stroma and immunosuppressive microenvironment. Accurately modeling this complex landscape and its immunosuppressive hallmarks in vitro is highly valuable for screening immunotherapeutic strategies. However, replicating these intricate features remains a significant challenge. Herein, we bioengineered miniaturized tumor-stroma platforms that combine cancer and stromal cells, as well as extracellular matrix mimetic biomaterials as a strategy to emulate the native tumor composition and key tumor immunosuppressive signatures. Bioengineered stratified tumor-stroma pancreatic cancer models, so termed cancer-on-a-bead platforms are generated in superhydrophobic surfaces and co-cultured with T cells, dendritic cells, as well as M0 macrophages, as a strategy to recapitulate tumor-immune interplay. The generated models revealed suppression of antigen presentation, M2 macrophage polarization, and T cell exhaustion, representing key features of this neoplasia. The screening of antibody mediated immunotherapy in the 3D tumor platforms, using clinically approved anti PD-1 antibody as a model therapeutic, partially restored T cell function. Overall, our findings demonstrate compartmentalized tumor-stroma models potential for being used to screen candidate immunotherapeutics for pancreatic cancer in a preclinical setting.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты